A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Na�ve Genotype 2

The primary objective is to evaluate, in treatment-naive subjects with chronic HCV GT-2 or -3 infection: � SVR12 following 24 weeks of treatment with Lambda/RBV and the SVR12 following 24 weeks of treatment with alfa-2a/RBV � SVR12 following 12 weeks of treatment with Lambda/RBV/DCV and the SVR12 following 24 weeks of treatment with alfa-2a/RBV